AR033622A1 - Compuestos aril oxima-piperazinas, composicion farmaceutica, el uso de dichos compuestos para la manufactura de medicamentos utiles como antagonistas de ccr5 y un equipo - Google Patents
Compuestos aril oxima-piperazinas, composicion farmaceutica, el uso de dichos compuestos para la manufactura de medicamentos utiles como antagonistas de ccr5 y un equipoInfo
- Publication number
- AR033622A1 AR033622A1 ARP020101139A ARP020101139A AR033622A1 AR 033622 A1 AR033622 A1 AR 033622A1 AR P020101139 A ARP020101139 A AR P020101139A AR P020101139 A ARP020101139 A AR P020101139A AR 033622 A1 AR033622 A1 AR 033622A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- compounds
- group
- ch2c
- independently selected
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 13
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- -1 aryl oxime piperazine compound Chemical class 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 125000006557 (C2-C5) alkylene group Chemical group 0.000 abstract 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 abstract 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 102000004274 CCR5 Receptors Human genes 0.000 abstract 1
- 108010017088 CCR5 Receptors Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000003003 spiro group Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27995001P | 2001-03-29 | 2001-03-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR033622A1 true AR033622A1 (es) | 2003-12-26 |
Family
ID=23071025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101139A AR033622A1 (es) | 2001-03-29 | 2002-03-27 | Compuestos aril oxima-piperazinas, composicion farmaceutica, el uso de dichos compuestos para la manufactura de medicamentos utiles como antagonistas de ccr5 y un equipo |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6689783B2 (https=) |
| EP (1) | EP1373206B1 (https=) |
| JP (1) | JP4303969B2 (https=) |
| KR (1) | KR20030083015A (https=) |
| CN (1) | CN1253435C (https=) |
| AR (1) | AR033622A1 (https=) |
| AT (1) | ATE418542T1 (https=) |
| AU (1) | AU2002303168B2 (https=) |
| CA (1) | CA2442210C (https=) |
| DE (1) | DE60230491D1 (https=) |
| ES (1) | ES2318009T3 (https=) |
| HU (1) | HUP0400389A3 (https=) |
| IL (1) | IL157713A0 (https=) |
| MX (1) | MXPA03008801A (https=) |
| MY (1) | MY134019A (https=) |
| NZ (1) | NZ528011A (https=) |
| WO (1) | WO2002079157A1 (https=) |
| ZA (1) | ZA200307171B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7825121B2 (en) * | 1999-05-04 | 2010-11-02 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
| PE20040769A1 (es) * | 2002-12-18 | 2004-11-06 | Schering Corp | Derivados de piperidina utiles como antagonisas ccr5 |
| EP1725235B1 (en) * | 2004-02-05 | 2009-04-15 | Schering Corporation | Piperidine derivatives useful as ccr3 antagonists |
| BRPI0509803A (pt) | 2004-04-13 | 2007-09-18 | Incyte Corp | derivados de piperazinilpiperidina como antagonistas de receptor de quimiocina |
| US20070215685A1 (en) * | 2005-02-03 | 2007-09-20 | Yottamark, Inc. | System and Method of Product Identification Using a URL |
| JP4769257B2 (ja) * | 2005-02-23 | 2011-09-07 | シェーリング コーポレイション | ケモカインレセプターのインヒビターとして有用なピペリジニルピペラジン誘導体 |
| US20080108586A1 (en) * | 2006-09-06 | 2008-05-08 | Incyte Corporation | Combination therapy for human immunodeficiency virus infection |
| KR100830003B1 (ko) * | 2006-10-31 | 2008-05-15 | 씨제이제일제당 (주) | 결정성 ｓ-(-)-암로디핀 아디핀산 염 무수물 및 이의 제조방법 |
| US20080173808A1 (en) * | 2007-01-18 | 2008-07-24 | Schering Corporation | Process and device for response normalized liquid chromatography nanospray ionization mass spectrometry (rnlc-nsi-ms) |
| EP2741777B1 (en) | 2011-08-12 | 2017-01-18 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| AU2021222441A1 (en) | 2020-02-19 | 2022-09-22 | Ichilov Tech Ltd. | Improved antidepressant therapy |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4949314A (en) | 1966-08-16 | 1990-08-14 | The United States Of America As Represented By The Secretary Of The Navy | Method and means for increasing echo-ranging-search rate |
| US4211771A (en) | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| GB8327880D0 (en) | 1983-10-18 | 1983-11-16 | Ajinomoto Kk | Saccharomyces cerevisiae |
| US4569790A (en) | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
| US4604377A (en) | 1984-03-28 | 1986-08-05 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
| US4530787A (en) | 1984-03-28 | 1985-07-23 | Cetus Corporation | Controlled oxidation of microbially produced cysteine-containing proteins |
| IL76360A0 (en) | 1984-09-26 | 1986-01-31 | Takeda Chemical Industries Ltd | Mutual separation of proteins |
| US4748234A (en) | 1985-06-26 | 1988-05-31 | Cetus Corporation | Process for recovering refractile bodies containing heterologous proteins from microbial hosts |
| NZ230045A (en) * | 1988-08-05 | 1990-11-27 | Janssen Pharmaceutica Nv | 3-piperazinylbenzazole derivatives and pharmaceutical compositions |
| US5368854A (en) | 1992-08-20 | 1994-11-29 | Schering Corporation | Use of IL-10 to treat inflammatory bowel disease |
| US5464933A (en) | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
| AU4788396A (en) | 1995-02-16 | 1996-09-04 | Children's Medical Center Corporation | Inhibition of angiogenesis using interleukin-12 |
| CA2371583C (en) * | 1999-05-04 | 2005-09-13 | Schering Corporation | Piperazine derivatives useful as ccr5 antagonists |
-
2002
- 2002-03-27 EP EP02731174A patent/EP1373206B1/en not_active Expired - Lifetime
- 2002-03-27 KR KR10-2003-7012566A patent/KR20030083015A/ko not_active Withdrawn
- 2002-03-27 MX MXPA03008801A patent/MXPA03008801A/es active IP Right Grant
- 2002-03-27 AR ARP020101139A patent/AR033622A1/es unknown
- 2002-03-27 CN CNB028076567A patent/CN1253435C/zh not_active Expired - Fee Related
- 2002-03-27 NZ NZ528011A patent/NZ528011A/en unknown
- 2002-03-27 JP JP2002577784A patent/JP4303969B2/ja not_active Expired - Fee Related
- 2002-03-27 WO PCT/US2002/009490 patent/WO2002079157A1/en not_active Ceased
- 2002-03-27 HU HU0400389A patent/HUP0400389A3/hu unknown
- 2002-03-27 ES ES02731174T patent/ES2318009T3/es not_active Expired - Lifetime
- 2002-03-27 IL IL15771302A patent/IL157713A0/xx unknown
- 2002-03-27 CA CA002442210A patent/CA2442210C/en not_active Expired - Fee Related
- 2002-03-27 AT AT02731174T patent/ATE418542T1/de not_active IP Right Cessation
- 2002-03-27 US US10/107,992 patent/US6689783B2/en not_active Expired - Fee Related
- 2002-03-27 AU AU2002303168A patent/AU2002303168B2/en not_active Expired - Fee Related
- 2002-03-27 DE DE60230491T patent/DE60230491D1/de not_active Expired - Lifetime
- 2002-03-28 MY MYPI20021141A patent/MY134019A/en unknown
-
2003
- 2003-09-12 ZA ZA200307171A patent/ZA200307171B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1253435C (zh) | 2006-04-26 |
| HK1057211A1 (en) | 2004-03-19 |
| CN1500078A (zh) | 2004-05-26 |
| ATE418542T1 (de) | 2009-01-15 |
| HUP0400389A2 (hu) | 2004-08-30 |
| JP2004524360A (ja) | 2004-08-12 |
| DE60230491D1 (de) | 2009-02-05 |
| US20030087912A1 (en) | 2003-05-08 |
| US6689783B2 (en) | 2004-02-10 |
| CA2442210C (en) | 2009-09-08 |
| MY134019A (en) | 2007-11-30 |
| AU2002303168B2 (en) | 2005-10-06 |
| CA2442210A1 (en) | 2002-10-10 |
| NZ528011A (en) | 2004-08-27 |
| ES2318009T3 (es) | 2009-05-01 |
| IL157713A0 (en) | 2004-03-28 |
| ZA200307171B (en) | 2004-12-13 |
| EP1373206B1 (en) | 2008-12-24 |
| HUP0400389A3 (en) | 2008-03-28 |
| KR20030083015A (ko) | 2003-10-23 |
| EP1373206A1 (en) | 2004-01-02 |
| MXPA03008801A (es) | 2004-02-18 |
| WO2002079157A1 (en) | 2002-10-10 |
| JP4303969B2 (ja) | 2009-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR057786A2 (es) | Uso de compuestos derivados de piperazina utiles como antagonistas ccr5, para la preparacion de medicamentos | |
| AR033622A1 (es) | Compuestos aril oxima-piperazinas, composicion farmaceutica, el uso de dichos compuestos para la manufactura de medicamentos utiles como antagonistas de ccr5 y un equipo | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| AR040673A1 (es) | Inhibidores micobacterianos, composicion farmaceutica y proceso de preparacion del compuesto | |
| PE20030007A1 (es) | Inhibidores de aldosa reductasa del grupo de las piridazinonas | |
| RU2009148796A (ru) | Производные пиперидина/пиперазина | |
| AR045587A1 (es) | Derivados de acil piperazinas sustituidas, proceso de obtencion, uso y composiciones farmaceuticas que las contienen | |
| AR056511A1 (es) | Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4 | |
| PE20090733A1 (es) | Derivados de pirazina como bloqueadores de los canales de sodio epitelial | |
| AR066460A2 (es) | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos | |
| AR060658A1 (es) | Derivados de diceto-piperazina y piperidina como agentes antivirales | |
| AR076860A1 (es) | Derivados de 7-aril- 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos. | |
| PE20050460A1 (es) | COMPUESTOS HETEROCICLICOS COMO ANTAGONISTAS CaSR (RECEPTOR SENSIBLE AL CALCIO) | |
| PE20081845A1 (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
| AR053195A1 (es) | Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo | |
| PE20141681A1 (es) | Inhibidores de btk | |
| PE20040458A1 (es) | Piridinas sustituidas con actividad anti-angiogenica | |
| PE20091090A1 (es) | Derivados de piperidina como agonistas de receptores muscarinicos | |
| AR035612A1 (es) | 4-(piperidin-4-ilmetil)benzamidas, o sus sales, esteres o solvatos, composiciones farmaceuticas que los comprenden, usos de los mismos para preparar medicamentos, y un kit para utilizar en el tratamiento de una enfermedad cognitiva o neurodegenerativa | |
| PE20010912A1 (es) | Derivados arilamina y su aplicacion como agentes antitelomerasa | |
| AR036366A1 (es) | Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit | |
| AR066154A1 (es) | Derivados de piperidina / piperazina | |
| UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| AR049711A1 (es) | Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |